The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics - Takeaways - MDSpire

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

  • By

  • YunLong Yang

  • Jiang Fu

  • ShengJie Tang

  • Tao Liu

  • HaiYang Hu

  • HaiYang Guo

  • Long Wen

  • Yang Yang

  • ChengKuan Liu

  • GuiYan Yi

  • Li Yu

  • HaiNing Zhou

  • June 8, 2026

  • 0 min

Share

  • 1

    The gastrin-releasing peptide receptor (GRPR) is overexpressed in several malignancies, making it a target for imaging and radionuclide therapy.

  • 2

    Recent advancements in GRPR-targeted radioligands have improved their clinical utility in tumor imaging and therapy.

  • 3

    GRPR-targeted imaging has shown promising diagnostic value in prostate cancer, breast cancer, and gastrointestinal stromal tumors.

  • 4

    Challenges in GRPR-targeted therapy include receptor heterogeneity, normal tissue uptake, and the need for high-quality clinical evidence.

  • 5

    Future developments in GRPR-targeted applications may focus on ligand engineering and integrating imaging-based treatment assessments.

Original Source(s)

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

  • by YunLong Yang, Jiang Fu, ShengJie Tang, Tao Liu, HaiYang Hu, HaiYang Guo, Long Wen, Yang Yang, ChengKuan Liu, GuiYan Yi, Li Yu, HaiNing Zhou

  • June 8, 2026

Related Content

Digital Twins as catalysts for Whole Person Health Mind Body Medicine in Integrative Oncology

Feasibility of weekly patient-reported symptom monitoring using patients' own smartphones in outpatient cancer chemotherapy: the SMART-PRO study

Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential